RedHill Biopharma Ltd. Sponsored ADR Stock

$1.71

6.56%

Nasdaq, Jul 25, 10:00 pm CET

ISIN

US7574681034

Symbol

RDHL

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

RedHill Biopharma Ltd. Sponsored ADR Stock price

$1.71

-6,898.29 99.98% 5Y

Nasdaq, Closing price Fri, Jul 25 2025

-0.12 6.56%

ISIN

US7574681034

Symbol

RDHL

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Pharmaceuticals

Key metrics

Basic

Market capitalization

$4.2m

Enterprise Value

$-70.0k

Net debt

positive

Cash

$4.6m

Shares outstanding

12.9b

Valuation (TTM | estimate)

P/E

- | -

P/S

0.4 | 0.1

EV/Sales

negative | negative

EV/FCF

0.0

P/B

negative

Financial Health

Equity Ratio

-26.0%

Return on Equity

176.6%

ROCE

551.7%

ROIC

Debt/Equity

-0.1

Financials (TTM | estimate)

Revenue

$10.6m | $38.8m

EBITDA

$-22.4m | -

EBIT

$-23.1m | $-6.6m

Net Income

$-11.4m | -

Free Cash Flow

$-9.4m

Growth (TTM | estimate)

Revenue

-11.0% | 382.1%

EBITDA

-157.1% | -

EBIT

-161.8% | 54.6%

Net Income

-115.2% | -

Free Cash Flow

73.8%

EPS

$0.0

FCF per Share

$0.0

Short interest

1.2%

Employees

Rev per Employee

$230.0k

As a Free StocksGuide user, you can view scores for all 7,027 stocks worldwide.

Get Started for Free Today

RedHill Biopharma Ltd. Sponsored ADR Stock Analysis

Unlock Scores for Free

??

7 Analysts have issued a RedHill Biopharma Ltd. Sponsored ADR forecast:

6x Buy

86%

More details on Analyst Estimates Including Price Targets

7 Analysts have issued a RedHill Biopharma Ltd. Sponsored ADR forecast:

Buy

86%

Hold

14%

Analyst Estimates with Stock Price Targets

Financial data from RedHill Biopharma Ltd. Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Dec '24		+/- %
Revenue	11 11	11% 11% 100%
- Direct Costs	4.60 4.60	22% 22% 43%
Gross Profit	6.02 6.02	0% 0% 57%
- Selling and Administrative Expenses	24 24	51% 51% 230%
- Research and Development Expense	2.25 2.25	62% 62% 21%
EBITDA	-22 -22	157% 157% -211%
- Depreciation and Amortization	0.62 0.62	69% 69% 6%
EBIT (Operating Income) EBIT	-23 -23	162% 162% -217%
Net Profit	-11 -11	115% 115% -107%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

RedHill Biopharma Ltd. Sponsored ADR Stock News

Neutral

PRNewsWire

●

7 days ago

RedHill Receives Positive FDA Feedback on Pathway to Approval of Groundbreaking RHB-204 for Crohn's Disease

The positive FDA feedback allows for: A novel Phase 2 RHB-204[1] study, planned to be the first ever clinical study in a specifically defined Mycobacterium avium subspecies paratuberculosis infected (MAP-positive) Crohn's disease (CD) patient population Groundbreaking approach testing MAP as a root cause of CD, supporting RHB-204 as a potential paradigm-shifting therapy treating both the suspec...

Neutral

PRNewsWire

●

27 days ago

RedHill Biopharma Announces Recruitment Initiated into Expanded Phase 2 Opaganib/Darolutamide Combination Study in Advanced Prostate Cancer

Recruitment initiated into the Phase 2 opaganib plus darolutamide study in patients with advanced prostate cancer, sponsored by ANZUP, and supported by Bayer and Ramsay Hospital Research Foundation Precision medicine approach: The 60-patient Phase 2 study uses the PCPro™ lipid biomarker test to identify patients with poor prognosis most likely to benefit from the combination Led by Professor Li...

Neutral

PRNewsWire

●

3 months ago

RedHill Biopharma Secures Kukbo Asset Freeze Following RedHill's $8.25 Million Plus Legal Fees New York Supreme Court Summary Judgment Win

Korea's Incheon District Court attachment grant prevents asset disposal by Kukbo prior to enforcement , following the New York Supreme Court's approximately $8.25 million plus legal fees and costs summary judgment in favor of RedHill -- The New York Supreme Court dismissed all Kukbo's counterclaims -- Latest Court victory demonstrates RedHill's commitment to collection of the court-mandated awa...

More RedHill Biopharma Ltd. Sponsored ADR News

Company Profile

RedHill Biopharma Ltd. is a biopharmaceutical company focusing on the development and commercialization of proprietary drugs for the treatment of gastrointestinal diseases. It operates through the Commercial Operations segment and the Research & Development segment. The Commercial Operations segment covers all areas relating to the commercial sales and operating expenses directly related to that activity and is being performed by the Company's subsidiary in the United States. The Research & Development segment includes all activities related to the research and development of therapeutic candidates. The company was founded by Dror Ben-Asher and Ori Shilo on August 3, 2009 and is headquartered in Tel Aviv, Israel.

Head office	Israel
CEO	Dror Ben-Asher
Employees	35
Founded	2009
Website	www.redhillbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now